Intrinsic apoptotic and thioredoxin pathways in human prostate cancer cell response to histone deacetylase inhibitor

There is a great need to develop better mechanism-based therapies for prostate cancer. In this investigation, we studied four human prostate cancer cell lines, LNCaP, DU145, LAPC4, and PC3, which differ in response to the histone deacetylase inhibitor, suberoylanilide hydroxamic acid (vorinostat), a new anticancer drug. Examining the role of intrinsic mitochondrial caspase-dependent apoptosis and caspase-independent, reactive oxygen species (ROS) facilitated cell death, has provided an understanding of mechanisms that may determine the varied response to the histone deacetylase inhibitor. We found striking differences among these cancer cells in constitutive expression and response to suberoylanilide hydroxamic acid in levels of antiapoptotic and proapoptotic proteins, mitochondria membrane integrity, activation of caspases, ROS accumulation, and expression of thioredoxin, the major scavenger of ROS. Identifying these differences can have predictive value in assessing therapeutic response and identifying targets to enhance therapeutic efficacy.

[1]  H. Scher,et al.  The histone deacetylase inhibitor SAHA arrests cancer cell growth, up-regulates thioredoxin-binding protein-2, and down-regulates thioredoxin , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[2]  S. Willis,et al.  Life in the balance: how BH3-only proteins induce apoptosis. , 2005, Current opinion in cell biology.

[3]  H. Nakamura,et al.  Redox Regulation by Thioredoxin and Thioredoxin‐Binding Proteins , 2001, IUBMB life.

[4]  D. Mustacich,et al.  The role of the redox protein thioredoxin in cell growth and cancer. , 2000, Free radical biology & medicine.

[5]  P. Marks,et al.  A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[6]  P. Dent,et al.  Kinase 1 Activation Downregulation, and C-jun N-terminal Mediated by Oxidative Damage, Xiap Leukemia Cells through a Process B Activation Potentiates Apoptosis in Κ Nf- Inhibitor-induced Rela/p65 Acetylation and Blockade of Histone Deacetylase , 2005 .

[7]  Takeshi Inoue,et al.  Marker genes to predict sensitivity to FK228, a histone deacetylase inhibitor. , 2005, Biochemical pharmacology.

[8]  Jorge A. Almenara,et al.  Simultaneous activation of the intrinsic and extrinsic pathways by histone deacetylase (HDAC) inhibitors and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) synergistically induces mitochondrial damage and apoptosis in human leukemia cells. , 2003, Molecular cancer therapeutics.

[9]  P. Marks,et al.  Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[10]  C. Korch,et al.  Molecular characterization of human prostate carcinoma cell lines , 2003, The Prostate.

[11]  K. McEleny,et al.  Inhibitors of apoptosis proteins in prostate cancer cell lines , 2002, The Prostate.

[12]  S. Srinivasula,et al.  Structure-based discovery of an organic compound that binds Bcl-2 protein and induces apoptosis of tumor cells. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[13]  J. Isaacs,et al.  Enhanced Redundancy in Akt and Mitogen-activated Protein Kinase-induced Survival of Malignant versus Normal Prostate Epithelial Cells , 2004, Cancer Research.

[14]  Elias S. J. Arnér,et al.  Physiological functions of thioredoxin and thioredoxin reductase. , 2000, European journal of biochemistry.

[15]  M. Schober,et al.  Identification of differentially expressed genes by serial analysis of gene expression in human prostate cancer. , 2001, Cancer research.

[16]  Y. Ishii,et al.  Loss of Thioredoxin-Binding Protein-2/Vitamin D3 Up-Regulated Protein 1 in Human T-Cell Leukemia Virus Type I-Dependent T-Cell Transformation , 2004, Cancer Research.

[17]  Ricky W Johnstone,et al.  Histone deacetylase inhibitors in cancer therapy: is transcription the primary target? , 2003, Cancer cell.

[18]  M. Dokmanovic,et al.  Prospects: Histone deacetylase inhibitors , 2005, Journal of cellular biochemistry.

[19]  M. Gleave,et al.  A novel antisense oligonucleotide inhibiting several antiapoptotic Bcl-2 family members induces apoptosis and enhances chemosensitivity in androgen-independent human prostate cancer PC3 cells , 2005, Molecular Cancer Therapeutics.

[20]  F. Saatcioglu,et al.  Histone deacetylase inhibitors differentially mediate apoptosis in prostate cancer cells , 2005, The Prostate.

[21]  W. Lee,et al.  Suppression of tumorigenicity of human prostate carcinoma cells by replacing a mutated RB gene. , 1990, Science.

[22]  P. Marks,et al.  Apoptotic and autophagic cell death induced by histone deacetylase inhibitors , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[23]  N. Hail.  Mitochondria: A novel target for the chemoprevention of cancer , 2005, Apoptosis.

[24]  G. Perez,et al.  Role of thioredoxin in the response of normal and transformed cells to histone deacetylase inhibitors. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[25]  Hsueh-Kung Lin,et al.  Screening and identification of differentially expressed transcripts in circulating cells of prostate cancer patients using suppression subtractive hybridization , 2005, Molecular Cancer.

[26]  L. Schwartz,et al.  Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  M. Matsui,et al.  Identification of Thioredoxin-binding Protein-2/Vitamin D3 Up-regulated Protein 1 as a Negative Regulator of Thioredoxin Function and Expression* , 1999, The Journal of Biological Chemistry.

[28]  C. Sawyers,et al.  The PTEN/MMAC1 tumor suppressor phosphatase functions as a negative regulator of the phosphoinositide 3-kinase/Akt pathway. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[29]  Lucia Altucci,et al.  Inhibitors of histone deacetylases induce tumor-selective apoptosis through activation of the death receptor pathway , 2005, Nature Medicine.

[30]  Xiaodong Wang,et al.  Cytochrome C-mediated apoptosis. , 2003, Annual review of biochemistry.

[31]  M. Maines.  Current protocols in toxicology , 1999 .

[32]  Xiaodong Wang,et al.  A Small Molecule Smac Mimic Potentiates TRAIL- and TNFα-Mediated Cell Death , 2004, Science.

[33]  Rajvir Dahiya,et al.  Epigenetic changes in prostate cancer: implication for diagnosis and treatment. , 2005, Journal of the National Cancer Institute.

[34]  J. Trapani,et al.  Novel mechanisms of apoptosis induced by histone deacetylase inhibitors. , 2003, Cancer research.

[35]  R A Rifkind,et al.  Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo. , 2000, Cancer research.

[36]  A. Zelenetz,et al.  Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  A. Holmgren,et al.  Thioredoxin and glutaredoxin systems. , 2019, The Journal of biological chemistry.

[38]  A. Gulino,et al.  TrkAIII: A Novel Hypoxia-regulated Alternative TrkA Splice Variant of Potential Physiological and Pathological Importance , 2005, Cell cycle.

[39]  Taylor Murray,et al.  Cancer Statistics, 2001 , 2001, CA: a cancer journal for clinicians.

[40]  H. Scher,et al.  Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[41]  G. Steele,et al.  Intracellular heterogeneity in mitochondrial membrane potentials revealed by a J-aggregate-forming lipophilic cation JC-1. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[42]  D. Bernhard,et al.  The histone deacetylase inhibitor and chemotherapeutic agent suberoylanilide hydroxamic acid (SAHA) induces a cell-death pathway characterized by cleavage of Bid and production of reactive oxygen species , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[43]  L. Sokoll,et al.  Dissociation between androgen responsiveness for malignant growth vs. expression of prostate specific differentiation markers PSA, hK2, and PSMA in human prostate cancer models , 2003, The Prostate.